Wedding in sight between Alfa Wassermann and Sigma-Tau, two of the major pharmaceutical groups in Italy with a strong presence also at an international level. The merger project, announced by the two partners, provides for the establishment of a new entity, which will be the leader in Italy in the sector with a turnover of over 900 million euros.
In the new company will merge the pharmaceutical activities of the two groups, excluding the rare diseases business of Sigma-Tau and some financial investments in companies in the international pharma and rare diseases sector which will remain in the hands of the Cavazza family, current owner of 95% of Sigma-Tau.
At the end of the operation, which should be finalized by the end of April, the new company will be 75% owned by Golinelli family (Alfa Wassermann) and 20% to some members of the Cavazza family, while Intesa SanPaolo, already a shareholder of Sigma-Tau with 5%, will keep this stake.
